{"pmid":32426897,"title":"Heparin - an old drug with multiple potential targets in Covid-19 therapy.","text":["Heparin - an old drug with multiple potential targets in Covid-19 therapy.","A prominent clinical feature of severe Covid-19 infection is respiratory failure associated with pulmonary coagulopathy. Recent reports published in Thrombosis and Haemostasis show that treatment with low-molecular weight heparin (LMWH) decreases mortality in critically ill patients with sepsis-induced hypercoagulation, and thus argue for prophylactic administration of the anticoagulant. In addition, the authors point to non-anticoagulant activities of heparin, in particular anti-inflammatory effects with potential to prevent deterioration of the disease. We would like to use this opportunity to clarify the biochemical background of the diverse activities of heparin, and further, how this information may be exploited to generate more efficient treatment of the viral infection. Mechanisms to consider relate to the functional roles of proteins interacting with heparan sulfate (HS), a polysaccharide closely related to heparin.","J Thromb Haemost","Lindahl, Ulf","Li, Jin-Ping","32426897"],"abstract":["A prominent clinical feature of severe Covid-19 infection is respiratory failure associated with pulmonary coagulopathy. Recent reports published in Thrombosis and Haemostasis show that treatment with low-molecular weight heparin (LMWH) decreases mortality in critically ill patients with sepsis-induced hypercoagulation, and thus argue for prophylactic administration of the anticoagulant. In addition, the authors point to non-anticoagulant activities of heparin, in particular anti-inflammatory effects with potential to prevent deterioration of the disease. We would like to use this opportunity to clarify the biochemical background of the diverse activities of heparin, and further, how this information may be exploited to generate more efficient treatment of the viral infection. Mechanisms to consider relate to the functional roles of proteins interacting with heparan sulfate (HS), a polysaccharide closely related to heparin."],"journal":"J Thromb Haemost","authors":["Lindahl, Ulf","Li, Jin-Ping"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32426897","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/jth.14898","locations":["heparin","heparin","Heparin"],"e_drugs":["Heparin","Polysaccharides","Heparitin Sulfate","Heparin, Low-Molecular-Weight"],"topics":["Treatment"],"weight":1,"_version_":1667252837926567937,"score":9.490897,"similar":[{"pmid":32445064,"title":"Heparin resistance in COVID-19 patients in the intensive care unit.","text":["Heparin resistance in COVID-19 patients in the intensive care unit.","Patients with COVID-19 have a coagulopathy and high thrombotic risk. In a cohort of 69 intensive care unit (ICU) patients we investigated for evidence of heparin resistance in those that have received therapeutic anticoagulation. 15 of the patients have received therapeutic anticoagulation with either unfractionated heparin (UFH) or low molecular weight heparin (LMWH), of which full information was available on 14 patients. Heparin resistance to UFH was documented in 8/10 (80%) patients and sub-optimal peak anti-Xa following therapeutic LMWH in 5/5 (100%) patients where this was measured (some patients received both anticoagulants sequentially). Spiking plasma from 12 COVID-19 ICU patient samples demonstrated decreased in-vitro recovery of anti-Xa compared to normal pooled plasma. In conclusion, we have found evidence of heparin resistance in critically unwell COVID-19 patients. Further studies investigating this are required to determine the optimal thromboprophylaxis in COVID-19 and management of thrombotic episodes.","J Thromb Thrombolysis","White, D","MacDonald, S","Bull, T","Hayman, M","de Monteverde-Robb, R","Sapsford, D","Lavinio, A","Varley, J","Johnston, A","Besser, M","Thomas, W","32445064"],"abstract":["Patients with COVID-19 have a coagulopathy and high thrombotic risk. In a cohort of 69 intensive care unit (ICU) patients we investigated for evidence of heparin resistance in those that have received therapeutic anticoagulation. 15 of the patients have received therapeutic anticoagulation with either unfractionated heparin (UFH) or low molecular weight heparin (LMWH), of which full information was available on 14 patients. Heparin resistance to UFH was documented in 8/10 (80%) patients and sub-optimal peak anti-Xa following therapeutic LMWH in 5/5 (100%) patients where this was measured (some patients received both anticoagulants sequentially). Spiking plasma from 12 COVID-19 ICU patient samples demonstrated decreased in-vitro recovery of anti-Xa compared to normal pooled plasma. In conclusion, we have found evidence of heparin resistance in critically unwell COVID-19 patients. Further studies investigating this are required to determine the optimal thromboprophylaxis in COVID-19 and management of thrombotic episodes."],"journal":"J Thromb Thrombolysis","authors":["White, D","MacDonald, S","Bull, T","Hayman, M","de Monteverde-Robb, R","Sapsford, D","Lavinio, A","Varley, J","Johnston, A","Besser, M","Thomas, W"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32445064","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1007/s11239-020-02145-0","keywords":["covid-19","heparin","intensive care","thrombosis"],"locations":["optimal","thromboprophylaxis"],"e_drugs":["Heparin, Low-Molecular-Weight","Heparin"],"topics":["Treatment"],"weight":1,"_version_":1667600475927609344,"score":376.81143},{"pmid":32302462,"title":"ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A Comment.","text":["ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A Comment.","We read with interest the International Society on Thrombosis and Hemostasis interim guidance on recognition and management of coagulopathy in COVID-19 (1). We applaud this group's efforts in releasing a timely article on the pandemic impacting all regions of the globe. While we agree that this interim guidance addresses important considerations for monitoring the disease process, we believe that the proposed treatment strategy of prophylactic low molecular weight heparin (LMWH) to treat severe COVID-19 coagulopathy is an unconvincing strategy. Patients that are critically ill with COVID-19 have hallmark signs of disseminated intravascular coagulation (DIC)(2), and as noted in the ISTH interim guidance and our own clinical practice, thrombosis is the overwhelming phenotype with rare bleeding complications. We address this concern with the existing data on the severe hypercoagulable state of COVID-19 victims and advocate for consideration of systemic anticoagulation with unfractionated heparin to prevent life threatening micro- and macrovascular thrombosis to mitigate their associated consequences, up to and including progression of respiratory and organ failure.","J Thromb Haemost","Barrett, Christopher D","Moore, Hunter B","Yaffe, Michael B","Moore, Ernest E","32302462"],"abstract":["We read with interest the International Society on Thrombosis and Hemostasis interim guidance on recognition and management of coagulopathy in COVID-19 (1). We applaud this group's efforts in releasing a timely article on the pandemic impacting all regions of the globe. While we agree that this interim guidance addresses important considerations for monitoring the disease process, we believe that the proposed treatment strategy of prophylactic low molecular weight heparin (LMWH) to treat severe COVID-19 coagulopathy is an unconvincing strategy. Patients that are critically ill with COVID-19 have hallmark signs of disseminated intravascular coagulation (DIC)(2), and as noted in the ISTH interim guidance and our own clinical practice, thrombosis is the overwhelming phenotype with rare bleeding complications. We address this concern with the existing data on the severe hypercoagulable state of COVID-19 victims and advocate for consideration of systemic anticoagulation with unfractionated heparin to prevent life threatening micro- and macrovascular thrombosis to mitigate their associated consequences, up to and including progression of respiratory and organ failure."],"journal":"J Thromb Haemost","authors":["Barrett, Christopher D","Moore, Hunter B","Yaffe, Michael B","Moore, Ernest E"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32302462","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14860","keywords":["acute respiratory distress syndrome (ards)","anticoagulation","covid-19","disseminated intravascular coagulation","international society on thrombosis and haemostasis (isth)"],"locations":["ISTH"],"e_drugs":["Heparin, Low-Molecular-Weight","Heparin"],"topics":["Treatment"],"weight":1,"_version_":1666138494868652033,"score":352.40787},{"pmid":32425013,"title":"COVID-19 and coagulative axis: review of emerging aspects in a novel disease.","text":["COVID-19 and coagulative axis: review of emerging aspects in a novel disease.","Latest evidences from literature suggest that SARS-CoV-2 disease 2019 (COVID-19) is commonly complicated with coagulopathy and that disseminated intravascular coagulation is present in the majority of deceased patients. Particularly, conventional coagulation parameters appear to be significantly altered in patients with poor prognosis. A wide-ranging cross- talk between coagulative haemostasis and inflammation, as well as the activation of coagulation cascade during viral infections, are well established. Another important evidence which may explain coagulation disorders in COVID-19 is the increase of thrombus formation under conditions of hypoxia. Despite the exact pathophysiological mechanism of coronavirus-induced thromboembolism needs to be further investigated, this finding suggests that it is good practice to assess the risk of thrombosis in COVID-19 patients to improvethe clinical management in terms of anticoagulation therapy. Anticoagulants, mainly low-molecular-weight heparin (LMWH), should be tailored in patients meeting sepsis induced coagulopathy (SIC) criteria or with markedly elevated D-dimer. In this context, further studies are needed to optimise the decision making in therapeutic approach.","Monaldi Arch Chest Dis","Boccia, Matilde","Aronne, Luigi","Celia, Benito","Mazzeo, Grazia","Ceparano, Maria","D'Agnano, Vito","Parrella, Roberto","Valente, Tullio","Bianco, Andrea","Perrotta, Fabio","32425013"],"abstract":["Latest evidences from literature suggest that SARS-CoV-2 disease 2019 (COVID-19) is commonly complicated with coagulopathy and that disseminated intravascular coagulation is present in the majority of deceased patients. Particularly, conventional coagulation parameters appear to be significantly altered in patients with poor prognosis. A wide-ranging cross- talk between coagulative haemostasis and inflammation, as well as the activation of coagulation cascade during viral infections, are well established. Another important evidence which may explain coagulation disorders in COVID-19 is the increase of thrombus formation under conditions of hypoxia. Despite the exact pathophysiological mechanism of coronavirus-induced thromboembolism needs to be further investigated, this finding suggests that it is good practice to assess the risk of thrombosis in COVID-19 patients to improvethe clinical management in terms of anticoagulation therapy. Anticoagulants, mainly low-molecular-weight heparin (LMWH), should be tailored in patients meeting sepsis induced coagulopathy (SIC) criteria or with markedly elevated D-dimer. In this context, further studies are needed to optimise the decision making in therapeutic approach."],"journal":"Monaldi Arch Chest Dis","authors":["Boccia, Matilde","Aronne, Luigi","Celia, Benito","Mazzeo, Grazia","Ceparano, Maria","D'Agnano, Vito","Parrella, Roberto","Valente, Tullio","Bianco, Andrea","Perrotta, Fabio"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425013","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.4081/monaldi.2020.1300","e_drugs":["Heparin, Low-Molecular-Weight","Heparin"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667352728863506433,"score":336.2605},{"pmid":32470198,"title":"Clinical differentiation of anticoagulant and non-anticoagulant properties of heparin.","text":["Clinical differentiation of anticoagulant and non-anticoagulant properties of heparin.","I thank Lindahl and Li for their thoughtful comments on the non-anticoagulant properties of heparin.(1) Heightened awareness of hypercoagulability has made heparin part and parcel of the COVID-19 management algorithms. In addition, reports of prophylactic anticoagulation failure have triggered several trials where escalated doses of heparin are compared with standard doses with the aim of preventing thrombotic complications. At this juncture, we do need to consider where do the non-anticoagulant properties of heparin fit in the COVID-19 clinical context?","J Thromb Haemost","Thachil, Jecko","32470198"],"abstract":["I thank Lindahl and Li for their thoughtful comments on the non-anticoagulant properties of heparin.(1) Heightened awareness of hypercoagulability has made heparin part and parcel of the COVID-19 management algorithms. In addition, reports of prophylactic anticoagulation failure have triggered several trials where escalated doses of heparin are compared with standard doses with the aim of preventing thrombotic complications. At this juncture, we do need to consider where do the non-anticoagulant properties of heparin fit in the COVID-19 clinical context?"],"journal":"J Thromb Haemost","authors":["Thachil, Jecko"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32470198","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/jth.14933","topics":["Treatment"],"weight":1,"_version_":1668167110008766464,"score":321.11746},{"pmid":32220112,"title":"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.","text":["Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.","BACKGROUND: A relatively high mortality of severe coronavirus disease 2019 (COVID-19) is worrying, and the application of heparin in COVID-19 has been recommended by some expert consensus because of the risk of disseminated intravascular coagulation and venous thromboembolism. However, its efficacy remains to be validated. METHODS: Coagulation results, medications, and outcomes of consecutive patients being classified as having severe COVID-19 in Tongji hospital were retrospectively analyzed. The 28-day mortality between heparin users and nonusers were compared, as was a different risk of coagulopathy, which was stratified by the sepsis-induced coagulopathy (SIC) score or D-dimer result. RESULTS: There were 449 patients with severe COVID-19 enrolled into the study, 99 of them received heparin (mainly with low molecular weight heparin) for 7 days or longer. D-dimer, prothrombin time, and age were positively, and platelet count was negatively, correlated with 28-day mortality in multivariate analysis. No difference in 28-day mortality was found between heparin users and nonusers (30.3% vs 29.7%, P = .910). But the 28-day mortality of heparin users was lower than nonusers in patients with SIC score >/=4 (40.0% vs 64.2%, P = .029), or D-dimer >6-fold of upper limit of normal (32.8% vs 52.4%, P = .017). CONCLUSIONS: Anticoagulant therapy mainly with low molecular weight heparin appears to be associated with better prognosis in severe COVID-19 patients meeting SIC criteria or with markedly elevated D-dimer.","J Thromb Haemost","Tang, Ning","Bai, Huan","Chen, Xing","Gong, Jiale","Li, Dengju","Sun, Ziyong","32220112"],"abstract":["BACKGROUND: A relatively high mortality of severe coronavirus disease 2019 (COVID-19) is worrying, and the application of heparin in COVID-19 has been recommended by some expert consensus because of the risk of disseminated intravascular coagulation and venous thromboembolism. However, its efficacy remains to be validated. METHODS: Coagulation results, medications, and outcomes of consecutive patients being classified as having severe COVID-19 in Tongji hospital were retrospectively analyzed. The 28-day mortality between heparin users and nonusers were compared, as was a different risk of coagulopathy, which was stratified by the sepsis-induced coagulopathy (SIC) score or D-dimer result. RESULTS: There were 449 patients with severe COVID-19 enrolled into the study, 99 of them received heparin (mainly with low molecular weight heparin) for 7 days or longer. D-dimer, prothrombin time, and age were positively, and platelet count was negatively, correlated with 28-day mortality in multivariate analysis. No difference in 28-day mortality was found between heparin users and nonusers (30.3% vs 29.7%, P = .910). But the 28-day mortality of heparin users was lower than nonusers in patients with SIC score >/=4 (40.0% vs 64.2%, P = .029), or D-dimer >6-fold of upper limit of normal (32.8% vs 52.4%, P = .017). CONCLUSIONS: Anticoagulant therapy mainly with low molecular weight heparin appears to be associated with better prognosis in severe COVID-19 patients meeting SIC criteria or with markedly elevated D-dimer."],"journal":"J Thromb Haemost","authors":["Tang, Ning","Bai, Huan","Chen, Xing","Gong, Jiale","Li, Dengju","Sun, Ziyong"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32220112","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.1111/jth.14817","keywords":["d-dimer","coagulopathy","coronavirus disease 2019","low molecular weight heparin","sepsis"],"link_comment_in":"32239799","locations":["heparin","Tongji"],"e_drugs":["Heparin, Low-Molecular-Weight","Heparin"],"topics":["Treatment"],"weight":1,"_version_":1666138492313272321,"score":304.78497}]}